Catalyst

Slingshot members are tracking this event:

Novartis' (NVS) Dual Combination Bronchodilator Inhalation Powder for Treatment of Airflow Obstruction in Patients with Chronic Pulmonary Disease Approved by FDA

Source Link:
http://www.prnewswire.com/news-releases/fda-approves-new-novartis-dual-combination-bronchodilator-utibron-neohaler-for-patients-with-chronic-obstructive-pulmonary-disease-300169137.html

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
NVS
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Oct 29, 2015
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Utibron Neohaler, Chronic Bronchitis, Emphysema, Chronic Obstructive Pulmonary Disease, Cop
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.